Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity.
about
Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision makingDipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance.Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.Postprandial serum C-peptide value is the optimal index to identify patients with non-obese type 2 diabetes who require multiple daily insulin injection: Analysis of C-peptide values before and after short-term intensive insulin therapy.Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes.Determining predictors of early response to exenatide in patients with type 2 diabetes mellitusEfficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal-SClinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden.Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetesIs a switch from insulin therapy to liraglutide possible in Japanese type 2 diabetes mellitus patients?Insulin receptor signaling and glucagon-like peptide 1 effects on pancreatic beta cells.Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.The effects of liraglutide on both hypereosinophilic insulin allergy and the characteristics of anti-insulin antibodies in type 2 diabetes mellitus: a case report.Sustained expression of GLP-1 receptor differentially modulates β-cell functions in diabetic and nondiabetic mice.Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized cLiraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study.Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.Predictors of treatment response to liraglutide in type 2 diabetes in a real-world setting.
P2860
Q26992979-16D2B2CE-F7E1-4360-A590-3A2B66965A91Q33603416-CCAA1002-37F7-449A-9A2D-CA656578CE43Q33607736-D79DA050-1E3A-4745-B878-8C2C9D9BD9FAQ33607770-70AC24E8-801F-4A7B-92F2-760B9122B2ACQ34402107-DEF9C3BB-99A9-41F4-98DD-AE7475766859Q35061423-E7CB3F55-4C61-4884-B7E7-8F363CF2722CQ35192193-9CD99768-329C-4F56-90F3-C27961574D1FQ36989711-9D56ED84-5EC2-4174-AAF7-AD3E62B3F887Q36993549-1AB4FEC5-C7A0-42FC-9111-2E97E702E8C7Q37604582-7C7CF728-50B6-44AA-8473-1367F57F1E81Q38646665-E5BC283F-4884-467C-8C53-6F00518F2936Q40113914-46604D32-81EE-46C3-968F-0D0466C71E58Q40998901-BF6BB9D3-C097-4AFC-8A47-51CF5BD7495CQ42118961-F2999DF0-A3BF-46C5-8260-A2669E57CF67Q42155061-5B3F6B17-3936-429B-A2A0-F67BAB633F10Q47137262-84650F44-2080-4340-8E65-A51DDC2061EFQ47348380-472CBFB4-1E1E-4930-824E-CD1DD33B593CQ47594612-CCB809D2-9F89-427F-8680-7F2C91488B45Q48359540-38D10F8E-D9B0-482A-8DCF-DB94AE676154Q51741448-5C66CC2D-D615-40C6-8F85-C3153CB4C40C
P2860
Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@ast
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@en
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@nl
type
label
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@ast
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@en
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@nl
prefLabel
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@ast
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@en
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@nl
P2093
P2860
P1476
Liraglutide is effective in ty ...... us insulin-secreting capacity.
@en
P2093
Akihisa Imagawa
Hiromi Iwahashi
Iichiro Shimomura
Junji Kozawa
Kana Inoue
Kohei Okita
Norikazu Maeda
Ryuya Iwamoto
Susumu Kashine
Tetsuhiro Kitamura
P2860
P304
P356
10.1111/J.2040-1124.2011.00168.X
P577
2012-06-01T00:00:00Z